2021 IPO
Bolt Biotherapeutics Stock
Bolt Therapeutics plans to develop a novel format for T-cell mediated anti-tumour therapy.
Sign up today and learn more about Bolt Biotherapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Bolt Biotherapeutics Stock
Bolt Therapeutics plans to develop a novel format for T-cell mediated anti-tumour therapy.
Funding History
| March 2015 | $600K |
|---|---|
| September 2016 | $10.0M |
| August 2018 | $19.4M |
| February 2019 | $54.0M |
Management
President and CEO
Reiner Laus
Chief Business Officer
Grant Yonehiro
Chief Executive Officer and Director
CP Liu
Founder
Edgar Engleman
EquityZen Recognized As:
